BACCARANI, MICHELE
BACCARANI, MICHELE
DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE
18F-FDG PET early after radiotherapy in lymphoma patients.
2004-01-01 CASTELLUCCI P; ZINZANI P; NANNI C; FARSAD M; MORETTI A; ALINARI L; BATTISTA G; PETTINATO C; MARENGO M; BOSCHI S; CANINI R; BACCARANI M.; MONETTI N; FANTI S.
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma
2008-01-01 Zinzani P.L.; Tani M.; Fanti S.; Stefoni V.; Musuraca G.; Vitolo U.; Perrotti A.; Fina M.; Derenzini E.; Baccarani M.
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma.
2007-01-01 Vose JM; Panwalkar A; Belanger R; Coiffier B; Baccarani M; Gregory SA; Facon T; Fanin R; Caballero D; Ben-Yehuda D; Giles F.
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.
2008-01-01 Zinzani PL; Tani M; Fanti S; Stefoni V; Musuraca G; Castellucci P; Marchi E; Farsad M; Fina M; Pellegrini C; Alinari L; Derenzini E; de Vivo A; Bacci F; Pileri S; Baccarani M.
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.
2012-01-01 Zinzani P.L.; Tani M.; Pulsoni A.; De Renzo A.; Stefoni V.; Broccoli A.; Montini G.C.; Fina M.; Pellegrini C.; Gandolfi L.; Cavalieri E.; Torelli F.; Scopinaro F.; Argnani L.; Quirini F.; Derenzini E.; Rossi M.; Pileri S.; Fanti S.; Baccarani M.
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia
2011-01-01 IACOBUCCI I.; SAZZINI M.; GARAGNANI P.; FERRARI A.; BOATTINI A.; LONETTI A.; PAPAYANNIDIS C.; MANTOVANI V.; MARASCO E.; OTTAVIANI E.; SOVERINI S.; GIRELLI D.; LUISELLI D.; VIGNETTI M.; BACCARANI M.; MARTINELLI G.
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
2007-01-01 Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M.
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients.
2011-01-01 Malagola M; Skert C; Vignetti M; Piciocchi A; Martinelli G; Alimena G; Mecucci C; Testoni N; Iacobucci I; Clavio M; Gobbi M; Candoni A; Damiani D; Bocchia M; Lauria F; Zaccaria A; Mazza P; Visani G; Peli A; Colombi C; Cancelli V; Mancini M; Fo R; Martelli M; Cantore N; Raimondo FD; Petrini M; de Fabritiis P; Fioritoni G; Nobile F; Fabbiano F; Specchia G; Baccarani M; Coco FL; Amadori S; Mandelli F; Russo D.
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia
2005-01-01 Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M.
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
2006-01-01 Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G
Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation.
2004-01-01 ARPINATI M; CHIRUMBOLO G; URBINI B; BONIFAZI F; BANDINI G; SAUNTHARARAJAH Y; ZAGNOLI A; STANZANI M; FALCIONI S; PERRONE G; TURA S; BACCARANI M.; RONDELLI D.
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase.
2007-01-01 Curti A; Aluigi M; Pandolfi S; Ferri E; Isidori A; Salvestrini V; Durelli I; Horenstein AL; Fiore F; Massaia M; Piccioli M; Pileri SA; Zavatto E; D'Addio A; Baccarani M; Lemoli RM.
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications
2008-01-01 Luatti S.; Marzocchi G.; Ottaviani E.; Baldazzi C.; Stacchini M.; Gamberini C.; Salmi F.; Martinelli G.; Baccarani M.; Testoni N.
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis
2012-01-01 S Luatti; F Castagnetti; G Marzocchi; C Baldazzi; G Gugliotta; I Iacobucci; G Specchia; L Zanatta; G Rege-Cambrin; M Mancini; E Abruzzese; A Zaccaria; M G Grimoldi; A Gozzetti; G Ameli; M A Capucci; G Palka; P Bernasconi; F Palandri; F Pane; G Saglio; G Martinelli; G Rosti; M Baccarani; N Testoni; on behalf of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia
1998-01-01 Damiani D.; Michieli M.; Ermacora A.; Russo D.; Fanin R.; Zaja F.; Baraldo M.; Pea F.; Furlanut M.; Baccarani M.
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia.
2006-01-01 Piccaluga P.P.; Martinelli G.; Rondoni M.; Visani G;. Baccarani M.
Advances in the treatment for haematological malignancies.
2006-01-01 Piccaluga P. P.; Martinelli G; Baccarani M.
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis
2012-01-01 Soverini S; Martinelli G.; Rosti G.; Iacobucci I.; Baccarani M.
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia.
2005-01-01 PICCALUGA PP; MARTINELLI G; MALAGOLA M; RONDONI M; BONIFAZI F; BANDINI G; VISANI G; BACCARANI M.
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients
2013-01-01 Broccoli A;Stanzani M;Bandini G;Bonifazi F;Stefoni V;Pellegrini C;Derenzini E;Gandolfi L;Quirini F;Argnani L;Tschon M;Casadei B;Baccarani M;Zinzani PL
Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
---|---|---|---|---|---|---|
18F-FDG PET early after radiotherapy in lymphoma patients. | CASTELLUCCI P; ZINZANI P; NANNI C; FARSAD M; MORETTI A; ALINARI L; BATTISTA G; PETTINATO C; MARENGO M; BOSCHI S; CANINI R; BACCARANI M.; MONETTI N; FANTI S. | 2004-01-01 | CANCER BIOTHERAPY & RADIOPHARMACEUTICALS | - | 1.01 Articolo in rivista | - |
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma | Zinzani P.L.; Tani M.; Fanti S.; Stefoni V.; Musuraca G.; Vitolo U.; Perrotti A.; Fina M.; Derenzini E.; Baccarani M. | 2008-01-01 | CANCER | - | 1.01 Articolo in rivista | - |
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma. | Vose JM; Panwalkar A; Belanger R; Coiffier B; Baccarani M; Gregory SA; Facon T; Fanin R; Caballero D; Ben-Yehuda D; Giles F. | 2007-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. | Zinzani PL; Tani M; Fanti S; Stefoni V; Musuraca G; Castellucci P; Marchi E; Farsad M; Fina M; Pellegrini C; Alinari L; Derenzini E; de Vivo A; Bacci F; Pileri S; Baccarani M. | 2008-01-01 | ANNALS OF ONCOLOGY | - | 1.01 Articolo in rivista | - |
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. | Zinzani P.L.; Tani M.; Pulsoni A.; De Renzo A.; Stefoni V.; Broccoli A.; Montini G.C.; Fina M.; Pellegrini C.; Gandolfi L.; Cavalieri E.; Torelli F.; Scopinaro F.; Argnani L.; Quirini F.; Derenzini E.; Rossi M.; Pileri S.; Fanti S.; Baccarani M. | 2012-01-01 | ANNALS OF ONCOLOGY | - | 1.01 Articolo in rivista | - |
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia | IACOBUCCI I.; SAZZINI M.; GARAGNANI P.; FERRARI A.; BOATTINI A.; LONETTI A.; PAPAYANNIDIS C.; MANTOVANI V.; MARASCO E.; OTTAVIANI E.; SOVERINI S.; GIRELLI D.; LUISELLI D.; VIGNETTI M.; BACCARANI M.; MARTINELLI G. | 2011-01-01 | LEUKEMIA RESEARCH | - | 1.01 Articolo in rivista | - |
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. | Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M. | 2007-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. | Malagola M; Skert C; Vignetti M; Piciocchi A; Martinelli G; Alimena G; Mecucci C; Testoni N; Iacobucci I; Clavio M; Gobbi M; Candoni A; Damiani D; Bocchia M; Lauria F; Zaccaria A; Mazza P; Visani G; Peli A; Colombi C; Cancelli V; Mancini M; Fo R; Martelli M; Cantore N; Raimondo FD; Petrini M; de Fabritiis P; Fioritoni G; Nobile F; Fabbiano F; Specchia G; Baccarani M; Coco FL; Amadori S; Mandelli F; Russo D. | 2011-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia | Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M. | 2005-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. | Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G | 2006-01-01 | CLINICAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation. | ARPINATI M; CHIRUMBOLO G; URBINI B; BONIFAZI F; BANDINI G; SAUNTHARARAJAH Y; ZAGNOLI A; STANZANI M; FALCIONI S; PERRONE G; TURA S; BACCARANI M.; RONDELLI D. | 2004-01-01 | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | - | 1.01 Articolo in rivista | - |
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. | Curti A; Aluigi M; Pandolfi S; Ferri E; Isidori A; Salvestrini V; Durelli I; Horenstein AL; Fiore F; Massaia M; Piccioli M; Pileri SA; Zavatto E; D'Addio A; Baccarani M; Lemoli RM. | 2007-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | - |
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications | Luatti S.; Marzocchi G.; Ottaviani E.; Baldazzi C.; Stacchini M.; Gamberini C.; Salmi F.; Martinelli G.; Baccarani M.; Testoni N. | 2008-01-01 | LEUKEMIA RESEARCH | - | 1.01 Articolo in rivista | - |
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis | S Luatti; F Castagnetti; G Marzocchi; C Baldazzi; G Gugliotta; I Iacobucci; G Specchia; L Zanatta; G Rege-Cambrin; M Mancini; E Abruzzese; A Zaccaria; M G Grimoldi; A Gozzetti; G Ameli; M A Capucci; G Palka; P Bernasconi; F Palandri; F Pane; G Saglio; G Martinelli; G Rosti; M Baccarani; N Testoni; on behalf of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML | 2012-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia | Damiani D.; Michieli M.; Ermacora A.; Russo D.; Fanin R.; Zaja F.; Baraldo M.; Pea F.; Furlanut M.; Baccarani M. | 1998-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | - |
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. | Piccaluga P.P.; Martinelli G.; Rondoni M.; Visani G;. Baccarani M. | 2006-01-01 | EXPERT OPINION ON BIOLOGICAL THERAPY | - | 1.01 Articolo in rivista | - |
Advances in the treatment for haematological malignancies. | Piccaluga P. P.; Martinelli G; Baccarani M. | 2006-01-01 | EXPERT OPINION ON PHARMACOTHERAPY | - | 1.01 Articolo in rivista | - |
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis | Soverini S; Martinelli G.; Rosti G.; Iacobucci I.; Baccarani M. | 2012-01-01 | PHARMACOGENOMICS | - | 1.01 Articolo in rivista | - |
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. | PICCALUGA PP; MARTINELLI G; MALAGOLA M; RONDONI M; BONIFAZI F; BANDINI G; VISANI G; BACCARANI M. | 2005-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | - |
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients | Broccoli A;Stanzani M;Bandini G;Bonifazi F;Stefoni V;Pellegrini C;Derenzini E;Gandolfi L;Quirini F;Argnani L;Tschon M;Casadei B;Baccarani M;Zinzani PL | 2013-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |